- Identification of variants associated with response or resistance to an approved therapy for the patient’s disease.
- Identification of variants associated with response to a therapy associated with another clinical indication.
- Identification of variants associated with a therapy (s) in clinical development.
A Comprehensive Genomic Test for Solid Tumors
CancerPlex is a next generation DNA sequencing test for solid tumors. The specific coding regions of over 400 known cancer genes are simultaneously determined using a small amount of DNA extracted from tumor samples, including formalin-fixed, paraffin-embedded (FFPE) tissue and cell blocks from fine-needle aspirates or effusions. This analysis is performed in a single assay, simplifying and streamlining the test ordering process, and eliminating time consuming serial testing. Clinically actionable information unique to each patient’s tumor is consolidated into a simple report.
CancerPlex reveals missense changes, insertions and deletions, and previously described rearrangements of ALK, RET, and ROS.
CancerPlex sequences more than 1.5 million nucleotides in 435 genes.
